2025 Q4 -tulosraportti
8 päivää sitten
‧35 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 178
Myynti
Määrä
3 503
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 136 | - | - | ||
| 277 | - | - | ||
| 493 | - | - | ||
| 322 | - | - | ||
| 42 | - | - |
Ylin
3,14VWAP
Alin
2,94VaihtoMäärä
2 658 592
VWAP
Ylin
3,14Alin
2,94VaihtoMäärä
2 658 592
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 15.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 22.8.2025 | ||
2025 Q1 -tulosraportti 19.5.2025 | ||
2024 Q4 -tulosraportti 7.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10.2.Partner - someone with their finger on the pulse - when could that realistically happen? All things being equal, it should probably be okay soon, right? Short-term price: it's probably not unthinkable that 2.5-3 is the bottom now heading into spring and summer's FDA. The question is how much more the price can gain if a partnership agreement is put in place soon? Redeye has 8-9 as a base case - one probably shouldn't expect it to go quite that high in the next months - but 4-5 is probably just around the corner and relatively easily achievable as more people understand what half-year we are looking into here?
·6.2.Very good reading and financing is secured throughout 2026 :) We can lean back and hope for good news this year :) Ascelia Pharma publishes Q4 results yesterday at 08:32 ∙ News overview (AI) Ascelia Pharma, a research company, reported a reduced operating loss for the fourth quarter of 2025, with no revenue as expected. The company focuses on the ongoing FDA review process for its leading product candidate, Orviglance, and expects a transformative 2026 with potential FDA approval and a commercial launch in the USA. Discussions on strategic partnerships are progressing, and the company has secured financing to support operations until the end of 2026. Ascelia Pharma's operating loss for Q4 2025 fell to -15.8 MSEK, an improvement from -21.9 MSEK the year before. Net result after tax was -15.9 MSEK, resulting in a loss per share of -0.13 SEK. Cash and cash equivalents amounted to 49.9 MSEK, providing a financial runway until Q4 2026 and extending beyond the expected FDA decision for Orviglance. The New Drug Application (NDA) for Orviglance has been submitted to the FDA, with approval and a commercial launch in the USA via a partner expected in 2026. Discussions on a commercial partnership for Orviglance are progressing, with strong strategic interest from potential partners.·10.2.But is there anyone who has their finger on the pulse regarding a partnership agreement - so should it be imminent or are they taking it slowly now into spring with it?
·1 päivä sitten · MuokattuP.S.: If they don't get a partner, but FDA approval (personally assess good chances for approval, as it is the only current contrast agent for the target group, but there's always risk in these types of decisions), they have the option to build a sales organization themselves. I believe, however, they have calculated that it will require 30-50 employees, which will require further capital injection, but then they also get 100% of the sales themselves. It would be better with a partner who already sells in that market and perhaps can do it with 5-10 extra employees, whereby Ascelia would then also receive a low royalty, which hopefully will be offset by sales being able to increase faster and the launch risk being significantly reduced.- ·4.2.Does anyone have any expectations for Q4 on Feb 6th? Will they meet expectations, or will we go down?
·4.2.-:) It's hard to say - but there is both a presentation tomorrow and an earnings presentation on Friday. Hoping for some good news. https://www.inderes.dk/videos?tab=upcoming&onlyFollowed=1 
·21.1.less about panic they have control over FDA they believe there is a partner just around the corner and Julie stays for a period longer ( maybe to help Anton with the partner agreement so she finishes well and he gets a super start )·28.1. · MuokattuShe is becoming CEO at Gedea Biotech. It's probably a kind of promotion, so it's not that strange if she wants the big job that comes with it, if she is passionate about their product and if the opportunity arose now that she has simultaneously played out some of her role in Ascelia. It would, of course, be even better to conclude with a partnership and the start of sales. But if Magnus handles the partnership part and a partner takes care of sales, her role will be limited going forward. She could, however, have taken on new tasks, e.g., regarding the rest of the world. But she apparently got an attractive opportunity. https://gedeabiotech.com/2026/01/27/gedea-biotech-appoints-julie-waras-brogren-as-new-ceo-to-lead-the-company-into-its-commercialization-phase/ Good luck to Julie.
·8.1.I cannot quite understand why Ascella should be BELOW the issue price from the autumn when we know that FDA approves July 4 this year and the management very clearly announced on Dec 3 that they feel very confident with the process they are currently undertaking to find a partnership agreement ?(See the announcement from Dec 3 below here) Does anyone have an answer to my question ? SCELIA PHARMA: CONFIDENT WITH PROCESS LEADS TO PARTNERSHIP AGREEMENT – FOUC 3. December 2025 09:09 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Ascelia Pharma feels confident about being able to reach a partnership agreement for the contrast agent candidate Orviglance. "We are very confident that we have a process that will lead to a good agreement," said Andreas Norlin, Head of Research at Ascelia Pharma, during his presentation at Redeyes Life Science day on Wednesday. He added that "we are very confident that we have a process that will lead to a good agreement". Andreas Norlin emphasizes that a potential partnership for Orviglance "is an incredibly important issue for everyone involved". The US Food and Drug Administration FDA has set a target date for the final approval decision to July 3, 2026, a so-called PDUFA date, for Orviglance. Orviglance has been granted orphan drug status by the US Food and Drug Administration FDA for use as a contrast agent for magnetic resonance imaging of the liver in patients with severely impaired kidney function. According to Andreas Norlin, products with orphan drug status have the opportunity to achieve a better price. However, he does not want to go into more detail about what price Orviglance might achieve given the ongoing partnership discussions for the product. A potential partner is expected to be able to influence the price of Orviglance. Ascelia Pharma, however, has an idea of what price range is reasonable for Orviglance after a conducted market survey.·8.1.As a starting point, it's bad the longer time passes. If they (which I don't believe due to the target group etc., but which we cannot rule out) get rejected, then it's quite important that they have found a partner and preferably a decent upfront payment, so they have money to manage until a second attempt. I do believe they can raise money without. But it is clear that an upfront payment significantly reduces the risk. So it probably plays perhaps a small role that time passes without us having a partner. But it mostly seems like day traders who are trading the price a bit up and down at the moment. It seems very controlled.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
8 päivää sitten
‧35 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10.2.Partner - someone with their finger on the pulse - when could that realistically happen? All things being equal, it should probably be okay soon, right? Short-term price: it's probably not unthinkable that 2.5-3 is the bottom now heading into spring and summer's FDA. The question is how much more the price can gain if a partnership agreement is put in place soon? Redeye has 8-9 as a base case - one probably shouldn't expect it to go quite that high in the next months - but 4-5 is probably just around the corner and relatively easily achievable as more people understand what half-year we are looking into here?
- ·6.2.Very good reading and financing is secured throughout 2026 :) We can lean back and hope for good news this year :) Ascelia Pharma publishes Q4 results yesterday at 08:32 ∙ News overview (AI) Ascelia Pharma, a research company, reported a reduced operating loss for the fourth quarter of 2025, with no revenue as expected. The company focuses on the ongoing FDA review process for its leading product candidate, Orviglance, and expects a transformative 2026 with potential FDA approval and a commercial launch in the USA. Discussions on strategic partnerships are progressing, and the company has secured financing to support operations until the end of 2026. Ascelia Pharma's operating loss for Q4 2025 fell to -15.8 MSEK, an improvement from -21.9 MSEK the year before. Net result after tax was -15.9 MSEK, resulting in a loss per share of -0.13 SEK. Cash and cash equivalents amounted to 49.9 MSEK, providing a financial runway until Q4 2026 and extending beyond the expected FDA decision for Orviglance. The New Drug Application (NDA) for Orviglance has been submitted to the FDA, with approval and a commercial launch in the USA via a partner expected in 2026. Discussions on a commercial partnership for Orviglance are progressing, with strong strategic interest from potential partners.·10.2.But is there anyone who has their finger on the pulse regarding a partnership agreement - so should it be imminent or are they taking it slowly now into spring with it?·1 päivä sitten · MuokattuP.S.: If they don't get a partner, but FDA approval (personally assess good chances for approval, as it is the only current contrast agent for the target group, but there's always risk in these types of decisions), they have the option to build a sales organization themselves. I believe, however, they have calculated that it will require 30-50 employees, which will require further capital injection, but then they also get 100% of the sales themselves. It would be better with a partner who already sells in that market and perhaps can do it with 5-10 extra employees, whereby Ascelia would then also receive a low royalty, which hopefully will be offset by sales being able to increase faster and the launch risk being significantly reduced.
- ·4.2.Does anyone have any expectations for Q4 on Feb 6th? Will they meet expectations, or will we go down?·4.2.-:) It's hard to say - but there is both a presentation tomorrow and an earnings presentation on Friday. Hoping for some good news. https://www.inderes.dk/videos?tab=upcoming&onlyFollowed=1
- ·21.1.less about panic they have control over FDA they believe there is a partner just around the corner and Julie stays for a period longer ( maybe to help Anton with the partner agreement so she finishes well and he gets a super start )·28.1. · MuokattuShe is becoming CEO at Gedea Biotech. It's probably a kind of promotion, so it's not that strange if she wants the big job that comes with it, if she is passionate about their product and if the opportunity arose now that she has simultaneously played out some of her role in Ascelia. It would, of course, be even better to conclude with a partnership and the start of sales. But if Magnus handles the partnership part and a partner takes care of sales, her role will be limited going forward. She could, however, have taken on new tasks, e.g., regarding the rest of the world. But she apparently got an attractive opportunity. https://gedeabiotech.com/2026/01/27/gedea-biotech-appoints-julie-waras-brogren-as-new-ceo-to-lead-the-company-into-its-commercialization-phase/ Good luck to Julie.
- ·8.1.I cannot quite understand why Ascella should be BELOW the issue price from the autumn when we know that FDA approves July 4 this year and the management very clearly announced on Dec 3 that they feel very confident with the process they are currently undertaking to find a partnership agreement ?(See the announcement from Dec 3 below here) Does anyone have an answer to my question ? SCELIA PHARMA: CONFIDENT WITH PROCESS LEADS TO PARTNERSHIP AGREEMENT – FOUC 3. December 2025 09:09 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Ascelia Pharma feels confident about being able to reach a partnership agreement for the contrast agent candidate Orviglance. "We are very confident that we have a process that will lead to a good agreement," said Andreas Norlin, Head of Research at Ascelia Pharma, during his presentation at Redeyes Life Science day on Wednesday. He added that "we are very confident that we have a process that will lead to a good agreement". Andreas Norlin emphasizes that a potential partnership for Orviglance "is an incredibly important issue for everyone involved". The US Food and Drug Administration FDA has set a target date for the final approval decision to July 3, 2026, a so-called PDUFA date, for Orviglance. Orviglance has been granted orphan drug status by the US Food and Drug Administration FDA for use as a contrast agent for magnetic resonance imaging of the liver in patients with severely impaired kidney function. According to Andreas Norlin, products with orphan drug status have the opportunity to achieve a better price. However, he does not want to go into more detail about what price Orviglance might achieve given the ongoing partnership discussions for the product. A potential partner is expected to be able to influence the price of Orviglance. Ascelia Pharma, however, has an idea of what price range is reasonable for Orviglance after a conducted market survey.·8.1.As a starting point, it's bad the longer time passes. If they (which I don't believe due to the target group etc., but which we cannot rule out) get rejected, then it's quite important that they have found a partner and preferably a decent upfront payment, so they have money to manage until a second attempt. I do believe they can raise money without. But it is clear that an upfront payment significantly reduces the risk. So it probably plays perhaps a small role that time passes without us having a partner. But it mostly seems like day traders who are trading the price a bit up and down at the moment. It seems very controlled.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 178
Myynti
Määrä
3 503
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 136 | - | - | ||
| 277 | - | - | ||
| 493 | - | - | ||
| 322 | - | - | ||
| 42 | - | - |
Ylin
3,14VWAP
Alin
2,94VaihtoMäärä
2 658 592
VWAP
Ylin
3,14Alin
2,94VaihtoMäärä
2 658 592
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 15.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 22.8.2025 | ||
2025 Q1 -tulosraportti 19.5.2025 | ||
2024 Q4 -tulosraportti 7.2.2025 |
2025 Q4 -tulosraportti
8 päivää sitten
‧35 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 15.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 22.8.2025 | ||
2025 Q1 -tulosraportti 19.5.2025 | ||
2024 Q4 -tulosraportti 7.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10.2.Partner - someone with their finger on the pulse - when could that realistically happen? All things being equal, it should probably be okay soon, right? Short-term price: it's probably not unthinkable that 2.5-3 is the bottom now heading into spring and summer's FDA. The question is how much more the price can gain if a partnership agreement is put in place soon? Redeye has 8-9 as a base case - one probably shouldn't expect it to go quite that high in the next months - but 4-5 is probably just around the corner and relatively easily achievable as more people understand what half-year we are looking into here?
- ·6.2.Very good reading and financing is secured throughout 2026 :) We can lean back and hope for good news this year :) Ascelia Pharma publishes Q4 results yesterday at 08:32 ∙ News overview (AI) Ascelia Pharma, a research company, reported a reduced operating loss for the fourth quarter of 2025, with no revenue as expected. The company focuses on the ongoing FDA review process for its leading product candidate, Orviglance, and expects a transformative 2026 with potential FDA approval and a commercial launch in the USA. Discussions on strategic partnerships are progressing, and the company has secured financing to support operations until the end of 2026. Ascelia Pharma's operating loss for Q4 2025 fell to -15.8 MSEK, an improvement from -21.9 MSEK the year before. Net result after tax was -15.9 MSEK, resulting in a loss per share of -0.13 SEK. Cash and cash equivalents amounted to 49.9 MSEK, providing a financial runway until Q4 2026 and extending beyond the expected FDA decision for Orviglance. The New Drug Application (NDA) for Orviglance has been submitted to the FDA, with approval and a commercial launch in the USA via a partner expected in 2026. Discussions on a commercial partnership for Orviglance are progressing, with strong strategic interest from potential partners.·10.2.But is there anyone who has their finger on the pulse regarding a partnership agreement - so should it be imminent or are they taking it slowly now into spring with it?·1 päivä sitten · MuokattuP.S.: If they don't get a partner, but FDA approval (personally assess good chances for approval, as it is the only current contrast agent for the target group, but there's always risk in these types of decisions), they have the option to build a sales organization themselves. I believe, however, they have calculated that it will require 30-50 employees, which will require further capital injection, but then they also get 100% of the sales themselves. It would be better with a partner who already sells in that market and perhaps can do it with 5-10 extra employees, whereby Ascelia would then also receive a low royalty, which hopefully will be offset by sales being able to increase faster and the launch risk being significantly reduced.
- ·4.2.Does anyone have any expectations for Q4 on Feb 6th? Will they meet expectations, or will we go down?·4.2.-:) It's hard to say - but there is both a presentation tomorrow and an earnings presentation on Friday. Hoping for some good news. https://www.inderes.dk/videos?tab=upcoming&onlyFollowed=1
- ·21.1.less about panic they have control over FDA they believe there is a partner just around the corner and Julie stays for a period longer ( maybe to help Anton with the partner agreement so she finishes well and he gets a super start )·28.1. · MuokattuShe is becoming CEO at Gedea Biotech. It's probably a kind of promotion, so it's not that strange if she wants the big job that comes with it, if she is passionate about their product and if the opportunity arose now that she has simultaneously played out some of her role in Ascelia. It would, of course, be even better to conclude with a partnership and the start of sales. But if Magnus handles the partnership part and a partner takes care of sales, her role will be limited going forward. She could, however, have taken on new tasks, e.g., regarding the rest of the world. But she apparently got an attractive opportunity. https://gedeabiotech.com/2026/01/27/gedea-biotech-appoints-julie-waras-brogren-as-new-ceo-to-lead-the-company-into-its-commercialization-phase/ Good luck to Julie.
- ·8.1.I cannot quite understand why Ascella should be BELOW the issue price from the autumn when we know that FDA approves July 4 this year and the management very clearly announced on Dec 3 that they feel very confident with the process they are currently undertaking to find a partnership agreement ?(See the announcement from Dec 3 below here) Does anyone have an answer to my question ? SCELIA PHARMA: CONFIDENT WITH PROCESS LEADS TO PARTNERSHIP AGREEMENT – FOUC 3. December 2025 09:09 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Ascelia Pharma feels confident about being able to reach a partnership agreement for the contrast agent candidate Orviglance. "We are very confident that we have a process that will lead to a good agreement," said Andreas Norlin, Head of Research at Ascelia Pharma, during his presentation at Redeyes Life Science day on Wednesday. He added that "we are very confident that we have a process that will lead to a good agreement". Andreas Norlin emphasizes that a potential partnership for Orviglance "is an incredibly important issue for everyone involved". The US Food and Drug Administration FDA has set a target date for the final approval decision to July 3, 2026, a so-called PDUFA date, for Orviglance. Orviglance has been granted orphan drug status by the US Food and Drug Administration FDA for use as a contrast agent for magnetic resonance imaging of the liver in patients with severely impaired kidney function. According to Andreas Norlin, products with orphan drug status have the opportunity to achieve a better price. However, he does not want to go into more detail about what price Orviglance might achieve given the ongoing partnership discussions for the product. A potential partner is expected to be able to influence the price of Orviglance. Ascelia Pharma, however, has an idea of what price range is reasonable for Orviglance after a conducted market survey.·8.1.As a starting point, it's bad the longer time passes. If they (which I don't believe due to the target group etc., but which we cannot rule out) get rejected, then it's quite important that they have found a partner and preferably a decent upfront payment, so they have money to manage until a second attempt. I do believe they can raise money without. But it is clear that an upfront payment significantly reduces the risk. So it probably plays perhaps a small role that time passes without us having a partner. But it mostly seems like day traders who are trading the price a bit up and down at the moment. It seems very controlled.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 178
Myynti
Määrä
3 503
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 136 | - | - | ||
| 277 | - | - | ||
| 493 | - | - | ||
| 322 | - | - | ||
| 42 | - | - |
Ylin
3,14VWAP
Alin
2,94VaihtoMäärä
2 658 592
VWAP
Ylin
3,14Alin
2,94VaihtoMäärä
2 658 592
Välittäjätilasto
Dataa ei löytynyt